Yes, the four indications are excluded- and given that it is what Neuren wants to target it should have zero effect re valuations. Also, if Neuren wanted to go after another indication, I don't think it would be retrospective ie Acadia would surely have to have had commenced planning/trials at least?
Ann: Q2 2023 quarterly activity and cash flow report, page-11
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.57 |
Change
0.025(0.20%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.61 | $12.68 | $12.34 | $1.640M | 131.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 183 | $12.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.57 | 33 | 2 |
View Market Depth
| Last trade - 10.40am 25/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |